{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=23",
    "query": {
      "intervention": "Cohorting",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 11334,
    "total_pages": 1134,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T15:17:03.467Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06501911",
      "title": "A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Recurrent High-grade Glioma"
      ],
      "interventions": [
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Intensity-modulated radiation therapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-04-08",
      "completion_date": "2025-07-17",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06501911"
    },
    {
      "nct_id": "NCT03515044",
      "title": "Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overt Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "40 mg Rifaximin SSD once daily",
          "type": "DRUG"
        },
        {
          "name": "40 mg Rifaximin SSD twice daily",
          "type": "DRUG"
        },
        {
          "name": "80 mg Rifaximin SSD once daily",
          "type": "DRUG"
        },
        {
          "name": "80 mg Rifaximin SSD twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 71,
      "start_date": "2018-09-13",
      "completion_date": "2020-03-12",
      "has_results": true,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 34,
      "location_summary": "Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Corona del Mar",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03515044"
    },
    {
      "nct_id": "NCT07462234",
      "title": "Continuous N-of-1 Computational Feasibility Study of a Whole Genome Sequence",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Computational Modeling of Individual Metabolic Pathways"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bioactify LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 1,
      "start_date": "2026-03-05",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 1,
      "location_summary": "Wappingers Falls, New York",
      "locations": [
        {
          "city": "Wappingers Falls",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07462234"
    },
    {
      "nct_id": "NCT04233034",
      "title": "Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "HCL",
          "type": "DEVICE"
        },
        {
          "name": "verapamil 120mg tablet",
          "type": "DRUG"
        },
        {
          "name": "non-HCL",
          "type": "DEVICE"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 113,
      "start_date": "2020-07-09",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233034"
    },
    {
      "nct_id": "NCT01198652",
      "title": "Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Postpartum Uterine Bleeding"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Glenveigh Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 300,
      "start_date": "2010-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2013-03-05",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Denver, Colorado • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Long Branch",
          "state": "New Jersey"
        },
        {
          "city": "Johnson City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01198652"
    },
    {
      "nct_id": "NCT04419649",
      "title": "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Cytopenia"
      ],
      "interventions": [
        {
          "name": "Elritercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2020-08-19",
      "completion_date": "2031-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 11,
      "location_summary": "Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419649"
    },
    {
      "nct_id": "NCT01061749",
      "title": "Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-11",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01061749"
    },
    {
      "nct_id": "NCT04523948",
      "title": "Comparative Tobacco Interventions for Individuals With Severe and Persisting Behavioral Health Disorders",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tobacco Use"
      ],
      "interventions": [
        {
          "name": "Behavioral and pharmacological support to reduce combustible tobacco use.",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rose Research Center, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-01-30",
      "completion_date": "2023-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-28",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04523948"
    },
    {
      "nct_id": "NCT05573126",
      "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor-positive Breast Cancer",
        "Hormone Receptor Positive HER-2 Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "EP0062",
          "type": "DRUG"
        },
        {
          "name": "Elacestrant",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ellipses Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2023-01-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05573126"
    },
    {
      "nct_id": "NCT03970278",
      "title": "Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glycogen Storage Disease Type IA",
        "Von Gierke's Disease (GSD Type Ia)"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-07-15",
      "completion_date": "2025-02-25",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-20T15:17:03.467Z",
      "location_count": 3,
      "location_summary": "Farmington, Connecticut • Ann Arbor, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970278"
    }
  ]
}